SCOPE 2020

Cognizant, Florence partner on clinical trial communication

By Jenni Spinner contact

- Last updated on GMT

(image: Getty/metamorworks)
(image: Getty/metamorworks)

Related tags: Florence Healthcare, Cognizant

The two firms have joined forces on technology designed to streamline collaboration between sites and sponsors.

During the SCOPE Summit clinical operations conference in Orlando, Florida, the two companies announced integration of Florence Healthcare’s eBinders electronic investigator site file (eISF) platform with the Cognizant Shared Investigator Platform (SIP).

According to Florence, the integration of the technologies enables sites to keep control of documents and data within Florence eBinders. At the same time, the integrated platform can activate exchanges with sponsors on the SIP via a single click.

Improved site communication

According to Ryan Jones, CEO of Florence, the successful exchange of requests and documents between the two systems marks the first successful step in the collaboration, which will enhance connectivity between clinical trial sites and their sponsors.

Jones told Outsourcing-Pharma that the company aims to “give research teams their day back”​ and save paperwork through use of electronic solutions.

“To fulfill this mission, we need to connect to the other tools that are important in the clinical research market,”​ he said. “SIP is one of those players, and we found the team to be open minded and excited to help site teams by connecting.”

Jones added that the SIP partnership enables industry sponsors to connect directly to Florence’s network of more than 6,300 research sites, so that they can more easily exchange documents and data.

Freeing the flow of data

Jones explained to us that the flow of documents and data between research sites and sponsors historically gets ‘stuck’ in binders, emails and portals. While other providers are noticing an opportunity to improve the process by creating solutions, he claimed, the Florence-Cognizant partnership is unique.

“Some pharmas are picking platforms that force the whole industry to pick one product​ that only meets pharma's needs,”​ he said. “Our philosophy is that the sites should pick the eISF that works best for them, the sponsors should pick the site management tool that works best for them, and then the two should integrate.”

Larissa Comis, SIP product lead at Cognizant, said many users of the platform are already familiar with Florence’s technology.

“As sponsors began to encounter Florence eBinders at a majority of their sites, we realized that integration was key to increasing efficiency and accelerating timelines,”​ she said.

The partnership is the latest move in a series by Florence to increase site-sponsor connectivity. In October 2019, Florence announced raising $7.1m (€6.5m) to build out a ‘sponsor portal​.’

Related news

Show more

Related products

show more

The Essential Clinical Development Resource Center

The Essential Clinical Development Resource Center

Data Management Solution Center | 05-Mar-2020 | Data Sheet

Clinical trials are becoming increasingly complex with oversight workloads increasing too. A recent survey based study conducted by Medidata in association...

Infographic:Transforming Data Capture & Management

Infographic:Transforming Data Capture & Management

Data Management Solution Center | 05-Mar-2020 | Infographic

Is your clinical study's data capture and management processes efficient? Medidata Rave Clinical Cloud is the only industry platform that creates...

Electronic Informed Consent and Global Regulation

Electronic Informed Consent and Global Regulation

Data Management Solution Center | 05-Mar-2020 | Technical / White Paper

Medidata is conducting an on-going study to understand global regulatory positions, adoption and variability regarding eConsent. The benefits of eConsent...

De-risk Go/No Go Product Development Decisions

De-risk Go/No Go Product Development Decisions

Data Management Solution Center | 05-Mar-2020 | Technical / White Paper

Learn how synthetic controls enable new insights for oncology clinical development and mitigates go/no-go decision risk. Synthetic control data can assist...

Related suppliers

Follow us

Products

View more

Webinars